Advances in Closed-Loop Insulin Delivery Systems in Patients with Type 1 Diabetes

Vikash Dadlani, Jordan E. Pinsker, Eyal Dassau, Yogish C. Kudva

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


Purpose of Review: To provide a current review of closed-loop insulin delivery or artificial pancreas (AP) as therapy for people with type 1 diabetes mellitus (T1D) Recent Findings: The Medtronic Minimed 670G AP system has been in use in clinical practice since March 2017. Currently, Medtronic is conducting a large randomized clinical trial to evaluate its efficacy further in T1D. Simultaneously, the NIH has funded four research consortia to accelerate progress to approval of other AP and decision support systems. Several research groups are currently developing next-generation AP systems, with a number of companies moving toward releasing closed-loop systems in the future. AP systems are also being tested in select populations such as hypoglycemia-unaware T1D and pregnant T1D. Summary: AP research is rapidly advancing. The clinical range of AP will be expanded in the next decade.

Original languageEnglish (US)
Article number88
JournalCurrent diabetes reports
Issue number10
StatePublished - Oct 1 2018


  • Artificial pancreas
  • Closed loop
  • Glycemic variability
  • Hypoglycemia
  • Type 1 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Advances in Closed-Loop Insulin Delivery Systems in Patients with Type 1 Diabetes'. Together they form a unique fingerprint.

Cite this